OGT gets exclusive access to Inven2's CRC biomarkers

Oxford Gene Technology (OGT) has entered into an exclusive licensing agreement with Inven2, the technology transfer office at Oslo University Hospital and University of Oslo, for 12 "highly promising" colorectal cancer (CRC) tissue biomarkers. The licence allows OGT to commercialise any resulting test developed using these biomarkers and to sub-license the markers to other parties. The DNA methylation biomarkers were developed in the laboratory of Professor Ragnhild A Lothe, in the department of Cancer Prevention, the Norwegian Radium Hospital, part of the Oslo University Hospital.

OGT has reviewed the results obtained in Lothe's laboratory, which show sensitivity of 93 per cent and specificity of 90 per cent when using tissue biopsies. Further work investigating the efficacy of these biomarkers in blood and faecal samples is ongoing.

This article is tagged to:
Sector: Medical Devices
Geography: Norway

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.